ECSP034898A - 2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS - Google Patents

2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS

Info

Publication number
ECSP034898A
ECSP034898A EC2003004898A ECSP034898A ECSP034898A EC SP034898 A ECSP034898 A EC SP034898A EC 2003004898 A EC2003004898 A EC 2003004898A EC SP034898 A ECSP034898 A EC SP034898A EC SP034898 A ECSP034898 A EC SP034898A
Authority
EC
Ecuador
Prior art keywords
compounds
disorders
crf
useful
methods
Prior art date
Application number
EC2003004898A
Other languages
English (en)
Inventor
Ping Ge
Yasuchika Yamaguchi
Dario Doller
Jianhua Huang
Kevin Hodggetts
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of ECSP034898A publication Critical patent/ECSP034898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se suministran compuestos de diarilpirazina, diarilpiridina y diarilpirimidina que actúan como moduladores selectivos de los receptores CRF 1. Estos compuestos son útiles en el tratamiento de un número de trastornos periféricos y del sistema nervioso central, particularmente estrés, ansiedad, depresión, trastornos cardiovasculares y trastornos de alimentación. Se suministran también métodos para tratar tales trastornos así como composiciones farmacéuticas empacadas. Los compuestos de fórmula I son también útiles para tratar de encontrar la localización de los receptores CRF y como patrones en los ensayos para unión del receptor CRF. Se suministran también métodos de uso de los compuestos en los estudios de localización del receptor.
EC2003004898A 2001-06-12 2003-12-12 2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS ECSP034898A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29748301P 2001-06-12 2001-06-12

Publications (1)

Publication Number Publication Date
ECSP034898A true ECSP034898A (es) 2004-01-28

Family

ID=23146501

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004898A ECSP034898A (es) 2001-06-12 2003-12-12 2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS

Country Status (16)

Country Link
US (2) US6887875B2 (es)
EP (1) EP1399428A1 (es)
JP (1) JP2005500286A (es)
AP (1) AP2003002924A0 (es)
BG (1) BG108427A (es)
CA (1) CA2450262A1 (es)
EC (1) ECSP034898A (es)
HR (1) HRP20031096A2 (es)
HU (1) HUP0400179A3 (es)
IL (1) IL159058A0 (es)
IS (1) IS7060A (es)
MX (1) MXPA03011391A (es)
PL (1) PL367476A1 (es)
RU (1) RU2003136151A (es)
TN (1) TNSN03133A1 (es)
WO (1) WO2002100838A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072521A1 (en) * 2000-03-16 2002-06-13 Taeyoung Yoon 5-substituted arylpyrimidines
MXPA04008384A (es) * 2002-04-26 2004-11-26 Upjohn Co Derivados de pirazina sustituidos.
ES2263058T3 (es) 2002-08-19 2006-12-01 Glaxo Group Limited Derivados de pirimidina como inhibidores selectivos de cox-2.
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1565454A1 (en) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Pyrazine compounds as crf modulators
EP1689740A1 (en) 2003-11-24 2006-08-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
US20080132522A1 (en) * 2004-07-14 2008-06-05 Basf Aktiengesellschaft 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
JP2009503103A (ja) 2005-08-02 2009-01-29 レキシコン・ファーマシューティカルズ・インコーポレーテッド アリールピリジン及びその使用方法
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
CA2779073C (en) * 2009-10-30 2017-10-24 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9351494B2 (en) 2013-05-03 2016-05-31 Inscent, Inc. Honeybee repellents and uses thereof
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
CN105254576A (zh) * 2014-02-26 2016-01-20 中国科学院长春应用化学研究所 一种谷氨酸二酮哌嗪的制备方法
JP2022074173A (ja) * 2019-03-18 2022-05-18 住友化学株式会社 ２，５－ジクロロピラジンの製造方法
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN113429354A (zh) * 2021-07-22 2021-09-24 广东嘉博制药有限公司 一种盐酸甲氧明聚合物杂质及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1458118A (fr) * 1964-02-26 1966-03-04 Ciba Geigy Nouveaux amino-phényl-alcanols et procédé pour leur préparation
US3660404A (en) * 1969-02-24 1972-05-02 Du Pont U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls
DE2064380C3 (de) * 1970-12-30 1981-01-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Gemisch
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
US4997942A (en) * 1988-04-25 1991-03-05 Dainippon Ink And Chemical, Inc. 2,4-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same
JPH02209873A (ja) * 1989-02-08 1990-08-21 Dainippon Ink & Chem Inc 光学活性２，５―ジ置換ピリミジン誘導体
JP2770385B2 (ja) * 1989-03-16 1998-07-02 セイコーエプソン株式会社 ピリミジン誘導体
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
JPH0948760A (ja) * 1995-08-03 1997-02-18 Dainippon Ink & Chem Inc ピリミジン化合物
JP4044175B2 (ja) * 1996-07-26 2008-02-06 株式会社半導体エネルギー研究所 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
CN1231440C (zh) * 1998-01-28 2005-12-14 盐野义制药株式会社 新的三环化合物
CO5210940A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen
KR20030031886A (ko) * 2000-02-16 2003-04-23 뉴로젠 코포레이션 치환된 아릴피라진

Also Published As

Publication number Publication date
PL367476A1 (en) 2005-02-21
TNSN03133A1 (en) 2005-12-23
US20030119844A1 (en) 2003-06-26
CA2450262A1 (en) 2002-12-19
HUP0400179A2 (hu) 2004-08-30
EP1399428A1 (en) 2004-03-24
IS7060A (is) 2003-11-28
JP2005500286A (ja) 2005-01-06
US6887875B2 (en) 2005-05-03
RU2003136151A (ru) 2005-05-20
BG108427A (en) 2005-01-31
US20050176721A1 (en) 2005-08-11
IL159058A0 (en) 2004-05-12
HUP0400179A3 (en) 2004-10-28
AP2003002924A0 (en) 2003-12-31
WO2002100838A1 (en) 2002-12-19
MXPA03011391A (es) 2004-07-01
HRP20031096A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
ECSP034898A (es) 2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS
UY28150A1 (es) Agentes terapeuticos
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
PA8615701A1 (es) Derivados de dihidrobenzofuranilo alcanamina y metodos para su uso.
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
UY28374A1 (es) Agentes terapéuticos
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
UY28752A1 (es) Agentes terapeuticos
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
UY28538A1 (es) Derivados de fenil-piperazina como moduladores de receptores muscarínicos
UY28839A1 (es) Agentes terapeuticos
ECSP034860A (es) 5-sustituidas-2-arilpiridinas como moduladores del factor 1 de liberación de corticotropina
CR9407A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
CR7735A (es) Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
MXPA05012572A (es) Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central.
CR7203A (es) 5-sustituidas-2-arilpiridinas como moduladores del factor 1 de liberacion de corticotropina
CR7201A (es) 2,5- diarilpirazinas, 2,5- diarilpiridinas y 2,5- diarilpirimidinas como moduladores del receptor crf1